INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023

    Date:

    INmune Bio (NASDAQ:INMB) just reported results for the fourth quarter of 2023.

    • INmune Bio reported earnings per share of -47 cents. This was below the analyst estimate for EPS of -44 cents.
    • The company reported revenue of $28,000.
    • This was 30% worse than the analyst estimate for revenue of $40,000.

    InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.

    Go Source

    Chart

    Sign up for Breaking Alerts

    Share post:

    Popular

    More like this
    Related

    Softer PMIs Propel Stocks Higher, Yields Lower: Apr. 23, 2024

    Corporate earnings are helping stocks scale the wall of...

    Understanding Gradient Descent Algorithm with Python Code

    Gradient Descent (GD) is the basic optimization algorithm for...

    All Eyes on Tesla Earnings Today

    The least magnificent of the “Magnificent Seven” so far...

    A Better Macro Policy Framework for Europe

    The new EU fiscal rules and the recently updated ECB monetary...